There is provided a CRF receptor antagonist comprising a compound of the
formula (I): ##STR00001## wherein, ring A is a 5-membered ring
represented by the formula (A'): ##STR00002## wherein X is a carbon and
X.sup.1 is an oxygen, a sulfur or --NR.sup.5--, or formula (A''):
##STR00003## wherein X is a nitrogen and R.sup.6 is an optionally
substituted hydrocarbyl, R.sup.1 is an amino substituted by two
optionally substituted hydrocarbyl groups, R.sup.2 is an phenyl, Y.sup.1
is CR.sup.3a or a nitrogen, Y.sup.2 is CR.sup.3b or a nitrogen and
Y.sup.3 is CR.sup.3c or a nitrogen, provided that one or less of Y.sup.1,
Y.sup.2, and Y.sup.3 is nitrogen, W is a bond, --(CH.sub.2)n-, and Z is a
bond, --NR.sup.4--, etc.; or a salt thereof or a prodrug thereof.
